

BCCA Protocol Summary for Palliative Chemotherapy for Advanced Head and Neck Nasopharyngeal Carcinoma with Weekly Cisplatin

Protocol Code

HNNAVP

Tumour Group

Head and Neck

BCCA Contact Physician

Cheryl Ho

ELIGIBILITY:

- Metastatic or unresectable head and neck nasopharyngeal carcinoma
- ECOG performance status 0 - 2
- Adequate marrow reserve (ANC greater than or equal to $1.5 \times 10^9/L$, platelets greater than $100 \times 10^9/L$)

EXCLUSIONS:

- Patients with inadequate renal function (creatinine clearance less than 60 ml/min by GFR measurement or Cockcroft formula)

TESTS:

- Baseline: CBC & differential, platelets, creatinine
- Before each treatment:
 - Day 1: CBC & differential, platelets, creatinine
 - Day 8: CBC & differential, platelets, creatinine

PREMEDICATIONS:

- Antiemetic protocol for high moderate emetogenic chemotherapy protocols (see protocol SCNAUSEA).

TREATMENT:

A Cycle equals -

Drug	Dose	BCCA Administration Guideline
Cisplatin	25 mg/m ² on days 1 and 8	IV in 100 mL NS over 30 min

Repeat every 14-21 days until disease progression or toxicity
Discontinue if no response after 2 cycles.

DOSE MODIFICATIONS:**1. Renal Dysfunction****For Cisplatin only**

Creatinine Clearance (ml/min)	Cisplatin dose
greater than or equal to 60ml/min	100%
45 - 59	50%
less than 45	Delay*
*Delay if day 1; if day 8, omit if <u>serum</u> creatinine greater than 3 x ULN	

Cockcroft-Gault Formula

$$\text{GFR} = \frac{\text{N}^* \times (140 - \text{age in years}) \times \text{wt (kg)}}{\text{serum creatinine (micromol/L)}}$$

*For males N = 1.23; for females N = 1.04

PRECAUTIONS:

- Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.
- Renal Toxicity:** Nephrotoxicity is common with cisplatin. Encourage oral hydration. Avoid nephrotoxic drugs such as aminoglycoside antibiotics. Use caution with pre-existing renal dysfunction.
- Pulmonary Toxicity:** Acute shortness of breath may occur. Discontinue treatment if drug-induced pneumonitis is suspected.

Call Dr Cheryl Ho or tumour group delegate at 1-888-563-7773 with any problems or questions regarding this treatment program.

Date activated: 1 Aug 2010

Date revised: 01 June 2011 (Infusion section revised)

References:

- Osoba, D. et al. Phase II study on the efficacy of weekly cisplatin-based chemotherapy in recurrent and metastatic head and neck Cancer. Ann Oncol 1992;3(Suppl.3):S57-S62.